RxSight vs Sanara MedTech
RXST and SMTI side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RXST and SMTI compare
Sanara MedTech is the larger company, worth 1.3 times as much as RxSight ($299M against $224M).
Sanara MedTech grew revenue faster over the last twelve months (9.8% versus −13.2% for RxSight).
Sanara MedTech keeps more of each dollar of sales as profit, with a net margin of −2.7% compared with −36.8% at RxSight.
RxSight scores higher on the StockData Score (10 against 7 for Sanara MedTech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RXST | SMTI |
|---|---|---|
| Size and price | ||
| Market cap | $224M | $299M |
| Share price | $5.38 | $32.54 |
| Change, 1 year | −47.4% | 16.0% |
| Change, 5 years | −60.2% | 3.9% |
| Beta (5Y) | 1.12 | 0.89 |
| Employees | 461 | 108 |
| StockData Score | ||
| Total score | 10 (better) | 7 |
| Valuation score | 3 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 1 | 3 (better) |
| Health score | 4 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.8× (better) | 2.7× |
| P/B | 0.8× (better) | 39.0× |
| EV/EBITDA | – | 37.8× |
| P/FCF | – | 41.0× |
| FCF yield | −12.1% | 2.4% (better) |
| Fair value | $20.63 | $10.41 |
| Margin of safety | 73.9% (better) | −213% |
| Growth | ||
| Revenue growth (TTM) | −13.2% | 9.8% (better) |
| Revenue growth, 5Y average | 55.7% (better) | 45.9% |
| Profitability | ||
| Gross margin | 77.5% | 93.0% (better) |
| Operating margin | −43.2% | 5.6% (better) |
| Net margin | −36.8% | −2.7% (better) |
| FCF margin | −21.3% | 6.5% (better) |
| Return on equity | −17.3% (better) | −43.7% |
| Return on invested capital | −82.9% | 13.3% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 6.10 (better) |
| Net debt / EBITDA | – | 3.44 |
| Interest coverage | −3674.3× | 0.9× (better) |
| Current ratio | 4.07 (better) | 2.24 |
| Altman Z-score | −0.55 | 3.47 (better) |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Buyback yield | −0.89% | – |
| Shareholder yield | −0.89% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 99.6% | 19.4% |
| Held by insiders | 5.4% | 14.9% |
| Insider net buying, 12 months | −$118K | – |
| Short interest, % of float | 9.2% | 5.3% |
Go deeper
- RXST stock overview
- RXST income statement
- RXST valuation and score
- SMTI stock overview
- SMTI income statement
- SMTI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.